Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients

American Heart Journal

Volumn 161, Issue 2, 2011, Pages 241-246

  Sellers, Matthew B ^a   Newby, L Kristin ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; CLOPIDOGREL; DABIGATRAN; PLACEBO; RIVAROXABAN; WARFARIN;

AGED; ANTICOAGULATION; ARTICLE; BLEEDING; DECISION MAKING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FALL RISK ASSESSMENT; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE;

EID: 79951473950     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.11.002     Document Type: Review

References (36)

1. Feinberg W.M., Blackshear J.L., and Laupacis A. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications Arch Intern Med 155 1995 469 473
2. Go A.S., Hylek E.M., and Phillips K.A. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370 2375 (Pubitemid 32424106)
3. Garwood C.L., and Corbett T.L. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls Ann Pharmacother 42 2008 523 532 (Pubitemid 351521967)
4. Lin H.J., Wolf P.A., and Kelly-Hayes M. Stroke severity in atrial fibrillation. The Framingham Study Stroke 27 1996 1760 1764 (Pubitemid 26332500)
5. Dharmarajan T.S., Varma S., and Akkaladevi S. To anticoagulate or not to anticoagulate? A common dilemma for the provider: physicians' opinion poll based on a case study of an older long-term care facility resident with dementia and atrial fibrillation J Am Med Dir Assoc 7 2006 23 28 (Pubitemid 43224338)
6. Man-Son-Hing M., and Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded Arch Intern Med 163 2003 1580 1586 (Pubitemid 36835103)
7. He J., Whelton P.K., Vu B., and Klag M.J. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials JAMA 280 1998 1930 1935 (Pubitemid 28559811)
8. Rosand J., Eckman M.H., and Knudsen K.A. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage Arch Intern Med 164 2004 880 884 (Pubitemid 38520629)
9. White R.H., Beyth R.J., and Zhou H. Major bleeding after hospitalization for deep-venous thrombosis Am J Med 107 1999 414 424 (Pubitemid 29528329)
10. Gage B.F., Birman-Deych E., and Kerzner R. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall Am J Med 118 2005 612 617 (Pubitemid 40732700)
11. Man-Son-Hing M., Nichol G., and Lau A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls Arch Intern Med 159 1999 677 685 (Pubitemid 29177656)
12. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators Arch Intern Med 157 1997 1237 1240
13. Hart R.G., Benavente O., and McBride R. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis Ann Intern Med 131 1999 492 501 (Pubitemid 29482392)
14. Fuster V., Ryden L.E., and Cannom D.S. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 2006 e257 354
15. Singer D.E., Albers G.W., and Dalen J.E. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 429S 456S (Pubitemid 39302603)
16. Fihn S.D., Callahan C.M., and Martin D.C. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics Ann Intern Med 124 1996 970 979
17. Fang M.C., Chang Y., and Hylek E.M. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation Ann Intern Med 141 2004 745 752
18. Hart R.G., Tonarelli S.B., and Pearce L.A. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas Stroke 36 2005 1588 1593 (Pubitemid 40967537)
19. Hylek E.M., Go A.S., and Chang Y. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N Engl J Med 349 2003 1019 1026 (Pubitemid 37087616)
20. White H.D., Gruber M., and Feyzi J. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V Arch Intern Med 167 2007 239 245
21. Mant J., Hobbs F.D., and Fletcher K. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial Lancet 370 2007 493 503 (Pubitemid 47212371)
22. Nichol M.B., Knight T.K., and Dow T. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care Ann Pharmacother 42 2008 62 70
23. Flaker G.C., Gruber M., and Connolly S.J. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials Am Heart J 152 2006 967 973 (Pubitemid 44637136)
24. SPAF II Investigators Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study Lancet 343 1994 687 691
25. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group Stroke 31 2000 817 821 (Pubitemid 30198421)
26. Bond A.J., Molnar F.J., and Li M. The risk of hemorrhagic complications in hospital in-patients who fall while receiving antithrombotic therapy Thromb J 3 2005 1
27. Connolly S.J., Yusuf S., and Budaj A. Rationale and design of ACTIVE: the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events Am Heart J 151 2006 1187 1193
28. ACTIVE Writing Group of the ACTIVE Investigators Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
29. Connolly S.J., Pogue J., and Hart R.G. Effect of clopidogrel added to aspirin in patients with atrial fibrillation N Engl J Med 360 2009 2066 2078
30. Connolly S.J., Ezekowitz M.D., and Yusuf S. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
31. U.S. Food and Drug Administration Web site FDA news release. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation (October 19, 2010) Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm230241.htm (accessed October 22, 2010).
32. Wood S., and O'Riordan M. FDA approves dabigatran for stroke prevention, embolism in AF patients. October 20, 2010 Available at: http://www.theheart.org/ article/1138703.do (accessed October 22, 2010)
33. Eikelboom J.W., O'Donnell M., and Yusuf S. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment Am Heart J 159 2010 348 353 e1
34. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study Am Heart J 159 2010 340 347 e1
35. Lopes R.D., Alexander J.H., and Al-Khatib S.M. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale Am Heart J 159 2010 331 339
36. Kangelaris K.N., Bent S., Nussbaum R.L., Garcia D.A., and Tice J.A. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin J Gen Intern Med 24 2009 656 664